Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Testen einer mobilen Gesundheitsanwendung zur Verbesserung der HIV-Prävention und Suchtmittelbehandlung bei Frauen im Justizsystem (PA-Links)

28. September 2026 aktualisiert von: Sarah Bass, Temple University

Entwicklung und Pilotierung einer mobilen Gesundheitsanwendung zur Verbesserung des Zugangs zu HIV-Prävention und Suchtbehandlungsdiensten für Frauen im Strafvollzugssystem

Women involved in the carceral system (WICS) are at higher risk for both HIV and substance use than the general public. WICS are also more likely to engage in behaviors both before and after release that put them at risk for HIV and for overdose, due to opioid use. Despite these risk factors, WICS are less likely to be aware of, use, or adhere to pre-exposure prophylaxis (PrEP) and have less access to medications for opioid use disorder (MOUD). The primary goal of the proposed research is to pilot test a systematically developed PrEP and MOUD uptake intervention for WICS using contextually relevant messages developed through novel formative research methods and embedded in a web-based application in a rigorous research design. The investigators will then test this approach (called PA-LINKS) in a pilot randomized trial with women who have recently been incarcerated in Philadelphia in partnership with Philadelphia FIGHT, a federally qualified health center, for promise of efficacy, and to assess feasibility and acceptability.

Studienübersicht

Detaillierte Beschreibung

The primary goal of the proposed research is to pilot test a systematically developed intervention for women who have been recently incarcerated to engage with pre-exposure prophalaxis (PrEP) and medication for opioid use disorder (MOUD) to prevent HIV infection and overdose. The intervention will use contextually relevant messages developed through novel formative research methods and be embedded in a web-based application called PA Links. The investigators will then test this approach in a pilot randomized trial with women who have recently been incarcerated. The purpose is to enhance communication in an existing post-release navigation model embedded in a community-based health services organization in Pennsylvania (Philadelphia FIGHT) to increase PrEP and MOUD uptake.

The app is meant to enhance communication among navigators, patients, and providers, as well as provide easy communication channels among participants for peer support. We will examine the feasibility/acceptability of the intervention with more traditional navigation support and examine preliminary data regarding its potential efficacy in engaging women in PrEP and MOUD.

For the pilot test, we will: 1. Conduct a pilot test with women who have recently been incarcerated (n=60) in Philadelphia randomized to an "Enhanced" intervention that includes patient navigation with the PA-Links web-based app + navigation, compared to a "Basic" intervention that includes existing navigation. To assess promise of efficacy, we will compare linkage to PrEP and MOUD (primary outcomes) during the three-month intervention at immediate post and 3-month follow-up and assess self-reported knowledge and attitudes. Qualitative exit interviews will inform feasibility and acceptability.

Studientyp

Interventionell

Einschreibung (Geschätzt)

74

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Sarah Bass, MPH, PhD
  • Telefonnummer: 215-204-0377
  • E-Mail: sbass@temple.edu

Studieren Sie die Kontaktsicherung

  • Name: Emily F Dauria, PhD
  • Telefonnummer: 412-383-0732
  • E-Mail: efd16@pitt.edu

Studienorte

    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19122
        • Temple University
        • Kontakt:
        • Kontakt:
        • Hauptermittler:
          • Sarah Bass, MPH

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • 18 of years of age or older
  • Self-identified woman
  • Previous experience (past six months) with the carceral system (jail, prison, on parole or under supervision)
  • Speaks and reads English
  • Self-reported negative HIV status
  • Indicates at least one HIV risk (i.e. any of the following in the past 6 months or in the six months prior to the most recent incarceration that call for consideration of PrEP as per the CDC risk indices: have engaged in condomless sex; have an HIV-positive sex partner; have had an STI; have had multiple [>6] partners; have engaged in transactional sex; have injected drugs, shared injection or drug use preparation equipment, or have been enrolled in opiate substitution therapy because of IDU; previous overdose)
  • Self-report using opioids in the past six months or six months prior to the most recent incarceration (prescription or not) OR self-report using medications for opioid use disorder in the past year.
  • Have access to the internet through some device - smart phone, computer or tablet (personal or at community location such as library or organization)

Exclusion Criteria:

  • Under 18 years old
  • Does not read or speak English
  • Does not identify as a woman
  • Has been diagnosed with HIV
  • Does not have previous experience with the criminal legal system within the last 6 months
  • Does not have HIV risk in last six months or six months prior to being incarcerated
  • Has not used opioids in past six months or six months prior to being incarcerated or MOUD in last year
  • Does not have access to internet
  • Cannot provide informed consent

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Kein Eingriff: Control Arm

For those participants randomized to the "Basic" arm of the intervention, standard of care navigation already provided by Philadelphia FIGHT will be provided, without the use of the PA Links application. Each participant will be assigned a navigator or care coordinator who will assist people by scheduling initial/first appointments, making appointment reminder calls, coordinating services, providing education, and facilitating communication among FIGHT departments. Navigation occurs from initial patient contact until the patient has their first visit. Then a care coordinator is assigned, who assists patients in overcoming ongoing barriers to care and doing similar tasks as the navigators after the first visit. Participants in the basic arm will thus receive all the services any other patient at FIGHT would receive.

Experimental: Intervention Arm

Women in the intervention arm will receive all the same navigation services at FIGHT along with access to the PA Links web-based app. This app will enhance the usual care by: 1. Sending up the three resources every week based on a participant's interests and needs. 2. Providing one quiz a week. At the beginning of each week of the intervention, participants will receive a pop-up message when they log in with a true/false question. 3. Sending at least two supportive messages a week. 4. Posting reminders and messages from navigators about appointments, medication use, or for other issues. 5. Being able to interact with other participants via an embedded communication widget.

The PA Links application is a web-based application (meaning it does not have to be downloaded to a smart phone and can be accessed via a URL link from any device connected to the Internet). This design ensures broader access and avoids excluding individuals without smartphones. This was developed along with our technology partner Nurelm (https://nurelm.com/).

Women randomized to this arm of the intervention will go through an onboarding session to assist them in creating a unique login username and password to the PA Links system (see onboarding document attached). Only those with a registered username and password can access and use the PA Links system and Nurelm will not be able to access the application after it is "live" for the pilot RCT. The application will be housed on the AWS server, which also does not have access to data or information in the app.

Andere Namen:
  • PA-Links

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Pre-exposure Prophylaxis (PrEP) linkage
Zeitfenster: Immediate post intervention (3 months)

Assess via medical record whether participant has been linked to PrEP services. Yes/No

Immediate post intervention (3 months)
Medications for Opioid Use Disorder (MOUD) Linkage
Zeitfenster: Immediate post intervention (3 months)

Assess via medical record whether participant has been linked to MOUD services. Yes/No

Immediate post intervention (3 months)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Engagement with intervention
Zeitfenster: Immediate post intervention (3 months)

Number and types of contact with navigator. Gotten from app data and EMR navigator reports

Immediate post intervention (3 months)
Usability of PA-Links
Zeitfenster: Immediate post intervention (3 months)

User logs on what parts of application were used most; Survey questions asking which parts of app they used, yes/no.

Immediate post intervention (3 months)
PrEP treatment referral
Zeitfenster: Immediate post intervention (3 months); Three month post intervention follow-up (six months)

Accepted referral to PrEP. Data from FIGHT EMR. Yes/no

Immediate post intervention (3 months); Three month post intervention follow-up (six months)
MOUD treatment referral
Zeitfenster: Immediate post intervention (3 months); Three month post intervention follow-up (six months)

Accepted MOUD treatment referral. Data from FIGHT EMR. Yes/No

Immediate post intervention (3 months); Three month post intervention follow-up (six months)
HIV Risk
Zeitfenster: Baseline, before intervention begins; Immediate post intervention (3 months); Three month post intervention follow-up (six months)

Self reported HIV behavior risk. Using the HIV Risk-Taking Behavior Scale. This scale is 11 items, assessing drug use and sexual behavior risk. Responses to each item are coded on a 6-point scale from 0 to 5, with higher values associated with more risky behaviors. Summary scores are obtained by adding up the ordinal values of responses obtained; a score of 0 would indicate no risky behaviors and a score of 55 would indicate maximal risky behaviors.

Baseline, before intervention begins; Immediate post intervention (3 months); Three month post intervention follow-up (six months)
Overdose risk
Zeitfenster: Baseline, before intervention begins; Immediate post intervention (3 months); Three month post intervention follow-up (six months)

Overdose risk and experience during intervention. Based on the Overdose Risk self-assessment, participants are asked about overdose risks answering yes or no. The more yes responses indicates a higher overdose risk.

Baseline, before intervention begins; Immediate post intervention (3 months); Three month post intervention follow-up (six months)
PrEP perceptions
Zeitfenster: Baseline, before intervention begins; Immediate post intervention (3 months); Three month post intervention follow-up (six months)

Perceptions of barriers and benefits to PrEP use. Study created scales - 12 statements on the benefits of using PrEP and 12 statements on barriers to using PrEP, answered on a zero -10 scale. Higher numbers mean higher agreement with the statement. These will be compared at the time points to assess if there is an increase in perceived benefits and a decrease in perceived barriers.

Baseline, before intervention begins; Immediate post intervention (3 months); Three month post intervention follow-up (six months)
MOUD perceptions
Zeitfenster: Baseline before intervention begins; Immediate post intervention (3 months); Three month intervention followup (6 months)

Perceptions of barriers and benefits to MOUD use. Study created scales - 11 statements on the benefits of using MOUD and 10 statements on barriers to using MOUD, answered on a zero -10 scale. Higher numbers mean higher agreement with the statement. These will be compared at the time points to assess if there is an increase in perceived benefits and a decrease in perceived barriers.

Baseline before intervention begins; Immediate post intervention (3 months); Three month intervention followup (6 months)
Time to Linkage of PrEP
Zeitfenster: Immediate post intervention (3 months); Three month post intervention follow-up (six months)

Time in months from navigator first contact to linkage to PrEP. EMR data from FIGHT.

Immediate post intervention (3 months); Three month post intervention follow-up (six months)
Receipt of prescription of PrEP
Zeitfenster: Immediate post intervention (3 months); Three month post intervention follow-up (six months)

Receipt of prescription of PrEP. EMR data from FIGHT. Yes/no

Immediate post intervention (3 months); Three month post intervention follow-up (six months)
Filling of PrEP prescription
Zeitfenster: Immediate post intervention (3 months); Three month post intervention follow-up (six months)

If PrEP prescription was filled. EMR data from FIGHT. Yes/No

Immediate post intervention (3 months); Three month post intervention follow-up (six months)
PrEP adherence
Zeitfenster: Immediate post intervention (3 months); 3 months intervention follow up (6 months)

Assess if participant is being adherent to PrEP based on FIGHT EMR data. Could be physician notes or blood work results, if taken. Yes/No

Immediate post intervention (3 months); 3 months intervention follow up (6 months)
PrEP knowledge
Zeitfenster: Baseline; Immediate intervention post-test (3 months); 3 month intervention follow-up (6 months)

True/False statements about PrEP. Five statements about PrEP. A composite score based on the number of correct answers will be assessed and compared across timepoints.

Baseline; Immediate intervention post-test (3 months); 3 month intervention follow-up (6 months)
Time to MOUD Linkage
Zeitfenster: Immediate post intervention (3 months); Three month post intervention follow-up (six months)

Time in months from navigator first contact to linkage to MOUD. EMR data from FIGHT.

Immediate post intervention (3 months); Three month post intervention follow-up (six months)
Receipt of MOUD Prescription
Zeitfenster: Immediate post intervention (3 months); 3 month post intervention follow-up (6 months)

Receipt of MOUD prescription. EMR data from FIGHT. Yes/no

Immediate post intervention (3 months); 3 month post intervention follow-up (6 months)
Filling of MOUD prescription
Zeitfenster: Immediate post intervention (3 months); 3 months intervention follow up (6 months)

Filling of MOUD prescription. EMR data from FIGHT. Yes/no

Immediate post intervention (3 months); 3 months intervention follow up (6 months)
MOUD adherence
Zeitfenster: Immediate post intervention (3 months); 3 months intervention follow up (6 months)

Assess if participant in adherent to MOUD based on FIGHT EMR data. Could be from physician notes or blood work, if taken. Yes/No

Immediate post intervention (3 months); 3 months intervention follow up (6 months)
MOUD Knowledge
Zeitfenster: Baseline; Immediate intervention post -test (3 months); 3 month intervention follow-up (six months)

True/False statements about MOUD. Five statements about MOUD. A composite score based on the number of correct answers will be assessed and compared across timepoints.

Baseline; Immediate intervention post -test (3 months); 3 month intervention follow-up (six months)
Client Intervention Satisfaction
Zeitfenster: Immediate post intervention (3 months)

Assessed via survey using five items from the the Study Participant Feedback Questionnaire. Two items are yes/no answers. Yes answers indicate they agree they were informed about the study. Three questions are on a 0-4 scale, with a zero indicating they strongly disagree with the statement and a 4 that they strongly agree. Higher number answers indicate higher intervention satisfaction.

Immediate post intervention (3 months)
mHealth feasibility/satisfaction
Zeitfenster: Immediate post intervention (3 months)

Assessed using the mHealth App Usability Questionnaire (MAUQ). It is a 21 item scale, with 8 items that assess Ease of use and satisfaction; 6 items on system information arrangement, and 7 items on usefulness. All use a 1 to 7 scale, indicating amount of agreement with a 7 as strongly agree. Each individual item will be assessed and a composite score for each area will also be assessed.

Immediate post intervention (3 months)
Usability of mHealth app
Zeitfenster: Immediate post intervention (3 months)

Assessed using the Usability of e-health interventions scale. It consists of 10 items scored on a 1-5 scale, indicating level of agreement, with a 5 meaning they strongly agree with the statement. The higher the score, the more they agree that the app was usable.

Immediate post intervention (3 months)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

20. Oktober 2026

Primärer Abschluss (Geschätzt)

30. Mai 2027

Studienabschluss (Geschätzt)

30. Mai 2027

Studienanmeldedaten

Zuerst eingereicht

13. Februar 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

23. Februar 2026

Zuerst gepostet (Tatsächlich)

25. Februar 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

28. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren